Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Merck restructuring Programs — Total Period Charges Across All Programs ($M) ($M)
Form 10-Q / 10-K Restructuring Footnote
Latest, Q2 2026
334
Period ended Jun 30, 2026
Change on a year earlier
-57.1%
779 in Q2 2025
History
38 quarters
Since Q1 2017
Sources
30
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Restructuring Programs — Total Period Charges Across All Programs ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 334 | -57.1% | Form 10-Q (filed 2026-08-07) ↗ |
| Q1 2026 | Mar 31, 2026 | 466 | +343.8% | Form 10-Q (filed 2026-05-04) ↗ |
| Q4 2025 | Dec 31, 2025 | 1,277 | +582.9% | Form 10-K (filed 2026-02-24) ↗ |
| Q3 2025 | Sep 30, 2025 | 390 | +39.8% | Form 10-Q (filed 2025-11-05) ↗ |
| Q2 2025 | Jun 30, 2025 | 779 | +342.6% | Form 10-Q (filed 2026-08-07) ↗ |
| Q1 2025 | Mar 31, 2025 | 105 | -57.3% | Form 10-Q (filed 2025-05-02) ↗ |
| Q4 2024 | Dec 31, 2024 | 187 | -53.4% | Form 10-K (filed 2025-02-25) ↗ |
| Q3 2024 | Sep 30, 2024 | 279 | +40.2% | Form 10-Q (filed 2024-11-06) ↗ |
| Q2 2024 | Jun 30, 2024 | 176 | -25.4% | Form 10-Q (filed 2024-08-05) ↗ |
| Q1 2024 | Mar 31, 2024 | 246 | +153.6% | Form 10-Q (filed 2025-05-02) ↗ |
| Q4 2023 | Dec 31, 2023 | 401 | +274.8% | Form 10-K (filed 2026-02-24) ↗ |
| Q3 2023 | Sep 30, 2023 | 199 | +13.7% | Form 10-Q (filed 2023-11-03) ↗ |
| Q2 2023 | Jun 30, 2023 | 236 | -8.5% | Form 10-Q (filed 2023-08-07) ↗ |
| Q1 2023 | Mar 31, 2023 | 97 | -23.6% | Form 10-Q (filed 2023-05-05) ↗ |
| Q4 2022 | Dec 31, 2022 | 107 | -55.0% | Form 10-K (filed 2023-02-24) ↗ |
| Q3 2022 | Sep 30, 2022 | 175 | +4.2% | Form 10-Q (filed 2023-11-03) ↗ |
| Q2 2022 | Jun 30, 2022 | 258 | +101.6% | Form 10-Q (filed 2023-08-07) ↗ |
| Q1 2022 | Mar 31, 2022 | 127 | -62.0% | Form 10-Q (filed 2023-05-05) ↗ |
| Q4 2021 | Dec 31, 2021 | 238 | -37.4% | Form 10-K (filed 2023-02-24) ↗ |
| Q3 2021 | Sep 30, 2021 | 168 | -9.2% | Form 10-Q (filed 2022-11-03) ↗ |
| Q2 2021 | Jun 30, 2021 | 128 | -14.1% | Form 10-Q (filed 2022-08-05) ↗ |
| Q1 2021 | Mar 31, 2021 | 334 | +98.8% | Form 10-Q (filed 2022-05-05) ↗ |
| Q4 2020 | Dec 31, 2020 | 380 | +39.2% | Form 10-K (filed 2023-02-24) ↗ |
| Q3 2020 | Sep 30, 2020 | 185 | -37.5% | Form 10-Q (filed 2021-11-05) ↗ |
| Q2 2020 | Jun 30, 2020 | 149 | -6.3% | Form 10-Q (filed 2021-08-09) ↗ |
| Q1 2020 | Mar 31, 2020 | 168 | -10.2% | Form 10-Q (filed 2021-05-05) ↗ |
| Q4 2019 | Dec 31, 2019 | 273 | +82.0% | Form 10-K (filed 2022-02-25) ↗ |
| Q3 2019 | Sep 30, 2019 | 296 | +75.1% | Form 10-Q (filed 2020-11-05) ↗ |
| Q2 2019 | Jun 30, 2019 | 159 | -32.3% | Form 10-Q (filed 2020-08-05) ↗ |
| Q1 2019 | Mar 31, 2019 | 187 | +79.8% | Form 10-Q (filed 2020-05-06) ↗ |
| Q4 2018 | Dec 31, 2018 | 150 | -53.4% | Form 10-K (filed 2021-02-25) ↗ |
| Q3 2018 | Sep 30, 2018 | 169 | -6.1% | Form 10-Q (filed 2019-11-05) ↗ |
| Q2 2018 | Jun 30, 2018 | 235 | +11.9% | Form 10-Q (filed 2019-08-06) ↗ |
| Q1 2018 | Mar 31, 2018 | 104 | -51.6% | Form 10-Q (filed 2019-05-08) ↗ |
| Q4 2017 | Dec 31, 2017 | 322 | – | Form 10-K (filed 2020-02-26) ↗ |
| Q3 2017 | Sep 30, 2017 | 180 | – | Form 10-Q (filed 2018-11-06) ↗ |
| Q2 2017 | Jun 30, 2017 | 210 | – | Form 10-Q (filed 2018-08-07) ↗ |
| Q1 2017 | Mar 31, 2017 | 215 | – | Form 10-Q (filed 2018-05-08) ↗ |
Breakdown
What makes up restructuring programs — total period charges across all programs ($m)
Cite this data
StockData. (2026). Merck Restructuring Programs — Total Period Charges Across All Programs ($M) ($M), quarterly Q1 2017–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/restr_total_all
See every metric in the Merck KPI table. Data updated Oct 26, 2026.